PMC4599040_01
Computed tomography scan of the lung before and after 14 months of gefitinib treatment.
ott-8-2739Fig1.jpg
PMC4599040_01_ott-8-2739Fig1.jpg
f1-ott-8-2739
Partial response (PR) was detected, and progression-free survival (PFS) lasted for 14 months (Figure 1).
Magnetic resonance imaging showing the disappearance of the paraspinal tumor after erlotinib treatment.
ott-8-2739Fig2.jpg
PMC4599040_01_ott-8-2739Fig2.jpg
f2-ott-8-2739
After the second administration of an EGFR-TKI, the paraspinal tumor disappeared (Figure 2), and tumors in both lungs shrank significantly (Figure 3).
Computed tomography scan showing that the lung tumor shrank significantly after erlotinib treatment.
ott-8-2739Fig3.jpg
PMC4599040_01_ott-8-2739Fig3.jpg
f3-ott-8-2739
After the second administration of an EGFR-TKI, the paraspinal tumor disappeared (Figure 2), and tumors in both lungs shrank significantly (Figure 3).